Dr. Maria Victoria Mateos is a Consultant Physician Haematology Department University Hospital of Salamanca, Spain where she is the Director of the Myeloma Unit and coordinates the Clinical Trials Unit. Dr. Mateos has wide-ranging research interests including the biology of plasma cells and new drug development and has organized numerous clinical trials in elderly patients and patients with smoldering myeloma. She is an advocate for early treatment of MM, especially subsets of smoldering MM patients that appear to benefit from early intervention, and as a consequence, her work has influenced treatment options within Spain and beyond.
Dr. Mateos received a medical degree from the University of Valladolid in Spain and completed her residency in Hematology at the University Hospital of Salamanca. She also undertook a doctoral degree investigating methylation of the p16 gene in multiple myeloma.
Dr. Mateos is a member of several professional societies. She sits on the European Hematology Association (EHA) Scientific Program Committee and Advisory Board, as well as on the American Society of Hematology’s Scientific Committee on Plasma Cell Diseases. She is a member of the European Society of Hematology (ESH) Scientific Committee and the Steering Committee for the Society of Hematologic Oncology (SOHO), and in 2015 was elected as a Councilor to the board of the EHA. She is also an active member of the International Myeloma Working Group (IMWG) and is part of the Education Committee for the International Myeloma Society (IMS). In her home country, she sits on the board of both the Spanish Myeloma Group (GEM) and the Programa para el Estudio de la Terapéutica en Hemopatía Maligna (PETHEMA).